Inhibition of HIV-1 replication by daunorubicin.
Members of the anthracycline family of drugs such as daunorubicin (DNR) are currently being employed in cancer therapy, treatment of Kaposi's sarcoma and lymphomas in HIV-1 infected patients. These drugs may have an anti-viral activity against HIV-1. Experiments conducted on U937 (a promonocytic cell line), peripheral blood monocytes (without T cells) and infected with HIV-1 showed anti-viral activity at nanogram/ml concentrations, without affecting cell proliferation and cell viability. Treatment of Hut 78 cells (a T cell line) with DNR was not as effective in inhibiting HIV-1 replication when compared to the anti-HIV activity in cells of the monocyte lineage.
Filion
L G
LG
Department of Microbiology and Immunology, University of Ottawa, Ontario.
Logan
D
D
Gaudreault
R
R
Izaguirre
C A
CA
D000998:Antiviral Agents / Q000494:pharmacology*; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D003630:Daunorubicin / Q000494:pharmacology*; D016655:HIV Core Protein p24 / Q000032:analysis; D015497:HIV-1 / Q000276:immunology / Q000502:physiology*; D006801:Humans; D009000:Monocytes / Q000382:microbiology; D011994:Recombinant Proteins; D013601:T-Lymphocytes / Q000382:microbiology; D014779:Virus Replication / Q000187:drug effects*
D000998:Antiviral Agents; D016655:HIV Core Protein p24; D011994:Recombinant Proteins; D003630:Daunorubicin